Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer.
OvCa
apoptosis
chemotherapy
drug development
dual topoisomerase inhibitor
hepatotoxicity
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
08
2021
accepted:
27
10
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
Ovarian cancer (OvCa) constitutes a rare and highly aggressive malignancy and is one of the most lethal of all gynaecologic neoplasms. Due to chemotherapy resistance and treatment limitations because of side effects, OvCa is still not sufficiently treatable. Hence, new drugs for OvCa therapy such as P8-D6 with promising antitumour properties have a high clinical need. The benzo[ In the present study, the effectiveness of P8-D6 on OvCa was investigated This study shows a significant P8-D6-induced increase in apoptosis and cytotoxicity in OvCa cells which surpasses the efficacy of well-established drugs like cisplatin or the topoisomerase inhibitors etoposide and topotecan. Non-cancer cells were affected only slightly by P8-D6. Moreover, no hepatotoxic effect in P8-D6 is a strong and rapid inductor of apoptosis and might be a novel treatment option for OvCa therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer (OvCa) constitutes a rare and highly aggressive malignancy and is one of the most lethal of all gynaecologic neoplasms. Due to chemotherapy resistance and treatment limitations because of side effects, OvCa is still not sufficiently treatable. Hence, new drugs for OvCa therapy such as P8-D6 with promising antitumour properties have a high clinical need. The benzo[
METHODS
METHODS
In the present study, the effectiveness of P8-D6 on OvCa was investigated
RESULTS
RESULTS
This study shows a significant P8-D6-induced increase in apoptosis and cytotoxicity in OvCa cells which surpasses the efficacy of well-established drugs like cisplatin or the topoisomerase inhibitors etoposide and topotecan. Non-cancer cells were affected only slightly by P8-D6. Moreover, no hepatotoxic effect in
CONCLUSION
CONCLUSIONS
P8-D6 is a strong and rapid inductor of apoptosis and might be a novel treatment option for OvCa therapy.
Identifiants
pubmed: 34887943
doi: 10.1177/17588359211059896
pii: 10.1177_17588359211059896
pmc: PMC8649464
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359211059896Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Références
J Clin Oncol. 2009 Mar 20;27(9):1419-25
pubmed: 19224846
Molecules. 2020 Mar 27;25(7):
pubmed: 32230817
Arch Toxicol. 2019 Mar;93(3):819-829
pubmed: 30560367
Nucleic Acids Res. 2009 Feb;37(3):738-48
pubmed: 19042970
J Control Release. 2015 Jul 28;210:198-207
pubmed: 25921087
Invest New Drugs. 1989 Nov;7(4):295-306
pubmed: 2557298
Cancer Chemother Pharmacol. 2013 Oct;72(4):917-23
pubmed: 23912694
Int J Nanomedicine. 2007;2(2):265-74
pubmed: 17722554
Mol Carcinog. 2013 Mar;52(3):167-82
pubmed: 22162252
Arch Gynecol Obstet. 2016 Aug;294(2):369-76
pubmed: 26825732
Anticancer Drugs. 1996 Feb;7(2):166-74
pubmed: 8740721
ChemMedChem. 2017 Mar 7;12(5):347-352
pubmed: 28099785
Commun Biol. 2020 May 19;3(1):246
pubmed: 32427948
J Med Chem. 2020 Feb 13;63(3):884-904
pubmed: 31592646
J Biol Chem. 2015 Apr 17;290(16):10126-35
pubmed: 25713076
J Ovarian Res. 2021 Mar 9;14(1):42
pubmed: 33750444
Ther Adv Med Oncol. 2018 Apr 11;10:1758835918768232
pubmed: 29662548
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005589
pubmed: 18425923
Oncologist. 2005 Oct;10(9):695-7
pubmed: 16249348
Prog Nucleic Acid Res Mol Biol. 2006;81:179-229
pubmed: 16891172
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancers (Basel). 2021 Apr 23;13(9):
pubmed: 33922533
Eur J Cancer. 1992;28A(4-5):743-8
pubmed: 1326304
Cancer Med. 2019 Nov;8(16):7018-7031
pubmed: 31560828
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
Gynecol Oncol. 2008 Jan;108(1):53-7
pubmed: 17904208
J Clin Oncol. 2001 Apr 1;19(7):2084-90
pubmed: 11283142
Cancer Res. 1991 Feb 15;51(4):1129-36
pubmed: 1705167
Zhonghua Fu Chan Ke Za Zhi. 2011 Mar;46(3):188-92
pubmed: 21575452
Methods Mol Biol. 2011;731:161-80
pubmed: 21516407
Gynecol Oncol. 2018 Feb;148(2):286-290
pubmed: 29248198
Curr Top Med Chem. 2003;3(3):339-53
pubmed: 12570767
Curr Med Chem. 2010;17(35):4270-90
pubmed: 20939813
Anticancer Drugs. 1999 Jan;10(1):17-23
pubmed: 10194543
Oncologist. 2001;6(2):162-76
pubmed: 11306728
J Clin Oncol. 1992 Apr;10(4):647-56
pubmed: 1312588